Related Experiment Video

Updated: Dec 25, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

557

Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma

Wancong Zhang1, Hanxing Zhao1, Jiasheng Chen1

  • 1Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China.

Life Sciences
|April 3, 2020
PubMed
Abstract

Insights

Janus kinase 2 (JAK2) is downregulated in skin cutaneous melanoma (SKCM), impacting patient prognosis and treatment response. This study clarifies JAK2's role in SKCM carcinogenesis and immune cell interactions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Skin cutaneous melanoma (SKCM) incidence is rising, with the Janus-STATs signaling pathway implicated in cancer progression.
  • The specific role of Janus kinases (JAKs) in SKCM pathogenesis remains unclear.
  • Understanding JAKs' function is crucial for improving SKCM patient outcomes.

Purpose of the Study:

  • To investigate the expression and gene regulation network of JAK2 in SKCM.
  • To elucidate the functional roles and prognostic significance of JAK2 in SKCM.
  • To explore the relationship between JAK2 expression and the tumor immune microenvironment.

Main Methods:

  • Utilized five online bioinformatics portals: GEPIA, TIMER, GeneMANIA, LinkedOmics, and GSCALite.
  • Analyzed JAK2 expression patterns in SKCM tissues.
  • Examined the gene regulatory network and functional associations of JAK2.

Main Results:

  • JAK2 expression was significantly downregulated in SKCM.
  • Downregulated JAK2 correlated with advanced pathological stage and poorer patient prognosis.
  • JAK2 functions involve DNA recombination, cell cycle, metabolism, NOD-like receptor, p53 signaling, and apoptosis pathways.
  • JAK2 levels associated with immune cell abundance and biomarkers.
  • Low JAK2 expression predicted resistance to specific targeted therapies (QL-VIII-58, TL-1-85, Ruxolitinib, TG101348, Sunitinib).

Conclusions:

  • JAK2 plays a significant role in SKCM development and progression.
  • JAK2 expression patterns and its regulatory network offer insights into SKCM carcinogenesis.
  • JAK2 may serve as a prognostic biomarker and a potential therapeutic target in SKCM.
Keywords:
BiomarkerJAK2STATSkin cutaneous melanoma

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.3K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K